Correction of the high blood viscosity syndrome by a mixture of diquertin and ascorbic acid in vitro and in vivo

• Published in: Phytotherapy research 2003-03, Vol.17 (3), p.276-278
• Main Authors: Plotnikov, M. B., Aliev, O. I., Maslov, M. Ju, Vasiliev, A. S., Tjukavkina, N. A.
• Format: Article
• Language: English
• Subjects: Animals; Antioxidants - administration & dosage; Antioxidants - pharmacology; Antioxidants - therapeutic use; ascorbic acid; Ascorbic Acid - administration & dosage; Ascorbic Acid - pharmacology; Ascorbic Acid - therapeutic use; Blood Viscosity - drug effects; Brain Ischemia - drug therapy; Brain Ischemia - pathology; cerebral ischemia; diquertin; Drug Therapy, Combination; Erythrocyte Aggregation - drug effects; Fibrinogen - drug effects; high blood viscosity syndrome; Male; Phytotherapy; Quercetin - administration & dosage; Quercetin - analogs & derivatives; Quercetin - pharmacology; Quercetin - therapeutic use; Rats; Rats, Wistar; rheological properties of blood
• ISSN: 0951-418X; 1099-1573
• DOI: 10.1002/ptr.1113

Diquertin was shown to diminish blood viscosity, to decrease the aggregation of erythrocytes, and to increase their deformability using a model of the high blood viscosity syndrome in vitro. A mixture of Diquertin with Ascorbic Acid was more effective in improving rheological indicators of blood, then either Diquertin or Tanakan. On a model of chronic brain ischemia, which is accompanied by significant deterioration of the rheological properties of blood, it was shown that a therapy with a mixture of Diquertin and Ascorbic Acid decreases the expression of the high blood viscosity syndrome. Copyright © 2003 John Wiley & Sons, Ltd.